Table 3 Hazard Ratio for Overall Survival & Sensitivity Analysis (2nd line ipilimumab vs historical controls)
Hazard Ratio (95% CI) | P-value | ||
|---|---|---|---|
Primary Analyses | Model A: Unadjusted Model | 0.65 (0.52–0.82) | 0.0003 |
Model B: IPTW Weighted Model | 0.62 (0.52–0.73) | < 0.0001 | |
Sensitivity Analyses | Model C: IPTW Weighted Model adjusting for 3rd line | 0.64 (0.53–0.76) | < 0.0001 |
Model D: IPTW Weighted Model adjusting for 3rd line checkpoint inhibitor treatment | |||
2nd line Ipilimumab | 0.63 (0.53–0.75) | < 0.0001 | |
Historical Controls | Ref | ||
Model E: Censoring patients at start of 3rd line | < 0.0001 | ||
2nd line Ipilimumab | 0.60 (0.48–0.73) | ||
Historical Controls | Ref | ||
Model F: Excluding patients who started 3rd line treatment | 0.0001 | ||
2nd line Ipilimumab (n = 122) | 0.67 (0.55–0.81) | ||
Historical Controls (n = 102) | Ref |